First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) — Hang Quach (2024) | RDL Network
First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Eben I. Lichtman, Amit Khot, Bradley Augustson, David Levitz, Hanlon Sia, Nicole Wong Doo, Michaela Liedtke, Camille Martinet, Vinu Menon, Andrew Garton, Harjeet Sembhi, Maria Pihlgren, Cyril Konto, Beata Holkova, Lida Pacaud, Hang Quach
Hang Quach, Bradley Augustson, David Levitz, Hanlon Sia, Eben I. Lichtman, Nicole Wong Doo, Michaela Liedtke, Camille Martinet, Vinu Menon, Andrew Garton, Cyril Konto, Lida Pacaud, Beata Holkova, Amit Khot
Andrew Garton, Vinu Menon, Hang Quach, Amit Khot, Bradley Augustson, Hanlon Sia, Nicole Wong Doo, David Levitz, Eben I. Lichtman, Michaela Liedtke, Camille Martinet, Beata Holkova, Harjeet Sembhi, Lida Pacaud, Sunitha Gn, Maria Pihlgren, Mario Perro, Cyril Konto
Shaji Kumar, Magdalini Migkou, Manisha Bhutani, Andrew Spencer, Sikander Ailawadhi, Anna Kalff, Farzana L. Walcott, Nabendu Pore, D. Gibson, Fujun Wang, Lily Cheng, Ioannis Kagiampakis, Marna Williams, Krista Kinneer, Yu Jiang, Jeffrey A. Zonder, Jeremy T. Larsen, Shreerang Sirdesai, Andrew J. Yee, Meletios A Dimopoulos
Meletios A Dimopoulos, Magdalini Migkou, Manisha Bhutani, Sikander Ailawadhi, Anna Kalff, Farzana L. Walcott, Nabendu Pore, Miranda Brown, Fujun Wang, Lily Cheng, Ioannis Kagiampakis, Marna Williams, Krista Kinneer, Yuling Wu, Yu Jiang, Robert Kubiak, Jeffrey A. Zonder, Jeremy T. Larsen, Shreerang Sirdesai, Andrew J. Yee, Shaji Kumar
Discussion(0)
No comments yet. Be the first to comment.